

# Yi-Wen Huang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4883549/publications.pdf>

Version: 2024-02-01

46  
papers

1,319  
citations

471509

17  
h-index

345221

36  
g-index

48  
all docs

48  
docs citations

48  
times ranked

1936  
citing authors

#	ARTICLE	IF	CITATIONS
1	Hepatic steatosis and development of type 2 diabetes: Impact of chronic hepatitis B and viral specific factors. <i>Journal of the Formosan Medical Association</i> , 2022, 121, 1478-1487.	1.7	12
2	Clinical Experience with Roppeginterferon Alfa-2b in the Off-Label Use for the Treatment of COVID-19 Patients in Taiwan. <i>Advances in Therapy</i> , 2022, 39, 910-922.	2.9	6
3	Novel long-acting ropeginterferon alfa-2b: Pharmacokinetics, pharmacodynamics and safety in a phase I clinical trial. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 2396-2407.	2.4	14
4	Impact of PNPLA3 p.I148M and Hepatic Steatosis on Long-Term Outcomes for Hepatocellular Carcinoma and HBsAg Seroclearance in Chronic Hepatitis B. <i>Journal of Hepatocellular Carcinoma</i> , 2022, Volume 9, 301-313.	3.7	11
5	Novel Pegylated Interferon for the Treatment of Chronic Viral Hepatitis. <i>Viruses</i> , 2022, 14, 1128.	3.3	11
6	Roppeginterferon Alfa-2b administered every two weeks for patients with genotype 2 chronic hepatitis C. <i>Journal of the Formosan Medical Association</i> , 2021, 120, 956-964.	1.7	15
7	Pharmacokinetics and Pharmacodynamics of Novel Long-Acting Roppeginterferon Alfa-2b in Healthy Chinese Subjects. <i>Advances in Therapy</i> , 2021, 38, 4756-4770.	2.9	10
8	Roppeginterferon alfa-2b in patients with genotype 1 chronic hepatitis C: Pharmacokinetics, safety, and preliminary efficacy. <i>JGH Open</i> , 2021, 5, 929-940.	1.6	14
9	Longitudinal change of metabolite profile and its relation to multiple risk factors for the risk of developing hepatitis B-related hepatocellular carcinoma. <i>Molecular Carcinogenesis</i> , 2020, 59, 1269-1279.	2.7	10
10	Roppeginterferon alfa-2b every 2 weeks as a novel pegylated interferon for patients with chronic hepatitis B. <i>Hepatology International</i> , 2020, 14, 997-1008.	4.2	18
11	New-onset diabetes increases risk of hepatic encephalopathy in cirrhotics with ascites: A nationwide cohort study. <i>Advances in Digestive Medicine</i> , 2019, 6, 93-100.	0.2	1
12	Smoking and Hepatitis B Virus-Related Hepatocellular Carcinoma Risk: The Mediating Roles of Viral Load and Alanine Aminotransferase. <i>Hepatology</i> , 2019, 69, 1412-1425.	7.3	26
13	Response to Hu et al.. <i>American Journal of Gastroenterology</i> , 2017, 112, 383-384.	0.4	1
14	Safety of Statins in Chronic Hepatitis B Patients. <i>American Journal of Gastroenterology</i> , 2017, 112, 385-386.	0.4	2
15	Response to Lo et al.. <i>American Journal of Gastroenterology</i> , 2017, 112, 387-388.	0.4	1
16	Effects of plant- and animal-based high-fat diets on lipid storage and distribution in environmental bacteria-colonized gnotobiotic mice. <i>Biochemical and Biophysical Research Communications</i> , 2017, 493, 1075-1081.	2.1	1
17	Long-term Nucleos(t)ides Analogues for Chronic Hepatitis B Improve Liver and Spleen Size: A Noninvasive Sonographic Study. <i>Journal of Medical Ultrasound</i> , 2017, 25, 161-166.	0.4	1
18	Nonalcoholic Fatty Liver Disease Is Exacerbated in High-Fat Diet-Fed Gnotobiotic Mice by Colonization with the Gut Microbiota from Patients with Nonalcoholic Steatohepatitis. <i>Nutrients</i> , 2017, 9, 1220.	4.1	120

#	ARTICLE	IF	CITATIONS
19	Multidisciplinary approach to optimize management of patients with chronic hepatitis C and alcoholic liver disease. <i>Journal of the Formosan Medical Association</i> , 2016, 115, 1097-1098.	1.7	0
20	Statins Reduce the Risk of Cirrhosis and Its Decompensation in Chronic Hepatitis B Patients: A Nationwide Cohort Study. <i>American Journal of Gastroenterology</i> , 2016, 111, 976-985.	0.4	89
21	Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients. <i>Liver International</i> , 2016, 36, 1755-1764.	3.9	177
22	Statins and the Risk of Cirrhosis and Its Decompensation in Chronic Hepatitis B Patients. <i>American Journal of Gastroenterology</i> , 2016, 111, 1655-1656.	0.4	3
23	On-Treatment Low Serum HBV RNA Level Predicts Initial Virological Response in Chronic Hepatitis B Patients Receiving Nucleoside Analogue Therapy. <i>Antiviral Therapy</i> , 2015, 20, 369-375.	1.0	61
24	Editorial: diabetes and its association with hepatocellular carcinoma in chronic hepatitis B authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 118-119.	3.7	2
25	Increased risk of hepatocellular carcinoma in chronic hepatitis C patients with new onset diabetes: a nationwide cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 902-911.	3.7	46
26	Increased risk of hepatocellular carcinoma in chronic hepatitis B patients with new onset diabetes: a nationwide cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 1200-1209.	3.7	49
27	Detectability and clinical significance of serum hepatitis B virus ribonucleic acid. <i>Hepatobiliary Surgery and Nutrition</i> , 2015, 4, 197-202.	1.5	6
28	Increased risk of cirrhosis and its decompensation in chronic hepatitis C patients with new-onset diabetes: A nationwide cohort study. <i>Hepatology</i> , 2014, 60, 807-814.	7.3	97
29	Reduced Toll-Like Receptor 9 Expression on Peripheral CD14 <sup>+</sup> Monocytes of Chronic Hepatitis B Patients and its Restoration by Effective Therapy. <i>Antiviral Therapy</i> , 2014, 19, 637-643.	1.0	18
30	Reply to: Modulation of Toll-like receptor 9 expression on monocytes of viral hepatitis patients. <i>Antiviral Therapy</i> , 2014, 20, 669-670.	1.0	0
31	Biphasic Pattern of Depression and Its Predictors during Pegylated Interferon-Based Therapy in Chronic Hepatitis B and C Patients. <i>Antiviral Therapy</i> , 2013, 18, 1-7.	1.0	8
32	A Genetic Screen Identifies Interferon- $\lambda$ Effector Genes Required to Suppress Hepatitis C Virus Replication. <i>Gastroenterology</i> , 2013, 144, 1438-1449.e9.	1.3	37
33	Increased Risk of Cirrhosis and Its Decompensation in Chronic Hepatitis B Patients With Newly Diagnosed Diabetes: A Nationwide Cohort Study. <i>Clinical Infectious Diseases</i> , 2013, 57, 1695-1702.	5.8	83
34	Reduced Toll-Like Receptor 3 Expression in Chronic Hepatitis B Patients and Its Restoration by Interferon Therapy. <i>Antiviral Therapy</i> , 2013, 18, 877-884.	1.0	40
35	Management of hepatitis B reactivation in patients receiving cancer chemotherapy. <i>Therapeutic Advances in Gastroenterology</i> , 2012, 5, 359-370.	3.2	20
36	Effect of Host and Viral Factors on Hepatitis B E Antigen-Positive Chronic Hepatitis B Patients Receiving Pegylated Interferon- $\lambda$ -2A Therapy. <i>Antiviral Therapy</i> , 2011, 16, 629-637.	1.0	91

#	ARTICLE	IF	CITATIONS
37	Serum hepatitis B surface antigen concentration correlates with HBV DNA level in patients with chronic hepatitis B. <i>Antiviral Therapy</i> , 2010, 15, 1133-1139.	1.0	80
38	Differential effects of interferon and lamivudine on serum HBV RNA inhibition in patients with chronic hepatitis B. <i>Antiviral Therapy</i> , 2010, 15, 177-184.	1.0	42
39	Complications of alcoholic liver cirrhosis: Active assessment by endoscopy and sonography. <i>Hepatology</i> , 2010, 52, 1864-1865.	7.3	11
40	Vitamin D receptor gene polymorphisms and distinct clinical phenotypes of hepatitis B carriers in Taiwan. <i>Genes and Immunity</i> , 2010, 11, 87-93.	4.1	41
41	Pathogenesis and management of alcoholic liver cirrhosis: a review. <i>Hepatic Medicine: Evidence and Research</i> , 2010, 3, 1.	2.5	10
42	Esophagogastric varices predict mortality in hospitalized patients with alcoholic liver disease in Taiwan. <i>Hepato-Gastroenterology</i> , 2010, 57, 305-8.	0.5	5
43	Human leukocyte antigenâ€œDRB1*1101 correlates with less severe hepatitis in Taiwanese male carriers of hepatitis B virus. <i>Journal of Medical Virology</i> , 2009, 81, 588-593.	5.0	6
44	Hepatitis B viral genotype in Taiwanese patients with acute hepatitis B. <i>Hepato-Gastroenterology</i> , 2008, 55, 633-5.	0.5	1
45	Discontinuation of lamivudine treatment for hepatitis flare after kidney or heart transplantation in hepatitis B surface antigen-positive patients: A retrospective case series. <i>Clinical Therapeutics</i> , 2006, 28, 1327-1334.	2.5	6
46	Higher cut-off index value of immunoglobulin M antibody to hepatitis B core antigen in Taiwanese patients with hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2006, 21, 859-862.	2.8	16